Small molecule · Modulator of p53 Y220C mutant protein (TP53) · developed by PMV Pharmaceuticals
Rezatapopt is an orally bioavailable small molecule that binds the crevice created by the TP53 Y220C mutation. It is designed to restore wild-type p53 protein structure and activity, which blocks tumor cell cycle progression and induces apoptosis in tumor cells carrying the mutant. It is studied in advanced solid tumors, including lung, ovarian, endometrial, breast, colorectal and head and neck cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04585750 | Phase 1/2 | Advanced Solid Tumor | Recruiting | PMVP |
| NCT06054464 | Phase 1 | Healthy Volunteers | Completed | PMVP |
| NCT05523687 | Phase 1 | Healthy Male Volunteers | Completed | PMVP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Malignant NeoplasmAdvanced Solid TumorBreast CancerColorectal CancerEndometrial CancerGall Bladder CancerHead and Neck CancerLocally AdvancedLung CancerMetastatic CancerMetastatic Solid TumorOther CancerOvarian CancerProstate Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the PMVP page.
See PMVP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PMVP catalysts and pipeline →